Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 4/2014

01.12.2014 | Multiple Myeloma (R Niesvizky, Section Editor)

Controversies in Multiple Myeloma: to Transplant or Not?

verfasst von: Isabel Ruth Preeshagul, Koen Van Besien, Tomer M. Mark

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The treatment of multiple myeloma (MM) has dramatically changed in the last decade due to the introduction of the immunomodulatory drugs (IMIDs) and proteasome inhibitors, otherwise known as the novel agents. Prior to the advent of the novel agents, the gold standard of treatment had been high-dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) for eligible candidates. Given the remarkable activity of the novel agents, and the significant morbidity of HDT/ASCT, the role of stem cell transplantation has now come into question. In this review, we explore the benefits and drawbacks to HDT/ASCT in the era of the novel therapies.
Literatur
1.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRef
2.
Blade J, Rosinol L, Cibeira M, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood. 2010;115(18):3655–63.PubMedCrossRef
3.
4.
Attal M, Harousseau J, Stoppa A, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91–7.PubMedCrossRef
5.
Child J, Morgan G, Davies F, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–83.PubMedCrossRef
6.
Kumar S, Rajkumar S, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20.PubMedCentralPubMedCrossRef
7.
Rajkumar S, Hayman S, Lacy M, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106(13):4050–3.PubMedCentralPubMedCrossRef
8.
Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075–85.PubMedCrossRef
9.
Sonneveld P, Schmidt-Wolf IG, Van Der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946–55.PubMedCrossRef
10.
Reeder C, Reece D, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337–41.PubMedCentralPubMedCrossRef
11.
Richardson P, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679–86.PubMedCentralPubMedCrossRef
12.
Richardson P, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557–60.PubMedCrossRef
13.
San Miguel JF, Schlag R, Khuageva N, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.PubMedCrossRef
14.
Niesvizky R, Jayabalan D, Christos P, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111(3):1101–9.PubMedCrossRef
15.
Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759–69.PubMedCrossRef
16.•
Rossi A, Mark T, Jayabalan D, et al. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013;121(11):1982–5. This is a retrospective study which directly investigates the differences between moving to ASCT at best response vs continuation of induction chemotherapy.PubMedCentralPubMedCrossRef
17.
Moreau P, Avet-Loiseau H, Harousseau J, Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 2011;29(14):1898–906.PubMedCrossRef
18.
Martinez-Lopez J, Blade J, Mateos MV et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118:529–34.
19.
Mcelwain T, Powles R. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2(8354):822–4.PubMedCrossRef
20.
Myeloma Trialists Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists’ Collaborative Group. J Clin Oncol. 1998;16(12):3832–42.
21.
Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115–23.PubMedCrossRef
22.
Attal M, Harousseau J, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–502.PubMedCrossRef
23.
Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106(12):3755–9.PubMedCrossRef
24.
Segeren C, Sonneveld P, Van Der Holt B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood. 2003;101(6):2144–51.PubMedCrossRef
25.
Koreth J, Cutler C, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007;13(2):183–96.PubMedCrossRef
26.
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–71.PubMedCrossRef
27.
Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol. 2005;32(4 Suppl 5):S24–30.PubMedCrossRef
28.
Rajkumar S, Blood E, Vesole D, Fonseca R, Greipp P. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24(3):431–6.PubMedCrossRef
29.
Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106(1):35–9.PubMedCrossRef
30.
Cavo M, Di Raimondo F, Zamagni E, et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol. 2009;27(30):5001–7.PubMedCrossRef
31.
Suppiah R, Srkalovic J, Hussein M. Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma. Clin Lymphoma Myeloma. 2006;6(4):301–5.PubMedCrossRef
32.
Gay F, Hayman S, Lacy M, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010;115(7):1343–50.PubMedCentralPubMedCrossRef
33.
Kumar S, Dispenzieri A, Lacy M, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21(9):2035–42.PubMedCrossRef
34.
Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2008;22(6):1280–1. Author reply 1281–2.PubMedCrossRef
35.
Giralt S, Stadtmauer E, Harousseau J, et al. International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009
36.
Mark T, Stern J, Furst J, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008;14(7):795–8.PubMedCentralPubMedCrossRef
37.
Micallef I, Ho A, Klein L, et al. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant. 2011;46(3):350–5.PubMedCrossRef
38.
Anderson K. Proteasome inhibitors in multiple myeloma. Semin Oncol. 2009;36(2 Suppl 1):S20–6.PubMedCrossRef
39.••
Cavo M, Rajkumar S, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063–73. Summary guidelines for selection and treatment of ASCT-eligible patients with MM.PubMedCentralPubMedCrossRef
40.
Egan J, Shi C, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120(5):1060–6.PubMedCentralPubMedCrossRef
41.
Kumar S, Lee J, Lahuerta J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–57.PubMedCentralPubMedCrossRef
42.
Kumar L, Iqbal N, Mookerjee A, et al. Complete response after autologous stem cell transplant in multiple myeloma. Cancer Med. 2014.
43.
Martino M, Postorino M, Gallo G, et al. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs. Clin Lymphoma Myeloma Leuk. 2014;14(2):148–54.PubMedCrossRef
44.
Fermand J, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92(9):3131–6.PubMed
45.••
Kumar S, Lacy M, Dispenzieri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer. 2012;118(6):1585–92. This retrospective study establishes that ASCT timing does not impact survival outcomes after induction with novel agents.PubMedCentralPubMedCrossRef
46.
Niesvizky R, Richardson P, Rajkumar S, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008
47.
Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28(15):2612–24.PubMedCrossRef
48.
Harousseau J, Dimopoulos M, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica. 2010;95(10):1738–44.PubMedCentralPubMedCrossRef
49.
Kapoor P, Kumar S, Dispenzieri A, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013;31(36):4529–35. This study highlights the correlation of disease response with clinical outcome post-ASCT.PubMedCrossRef
50.
Lahuerta J, Mateos M, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26(35):5775–82.PubMedCrossRef
51.
Wang M, Delasalle K, Feng L, et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant. 2010;45(3):498–504.PubMedCrossRef
52.••
Costa L, Zhang M, Zhong X, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013;19(11):1615–24. This retrospective analysis shows that the benefit of ASCT has not changed with the introduction of the novel agents.PubMedCentralPubMedCrossRef
53.
Alexanian R, Dimopoulos M, Delasalle K, Hester J, Champlin R. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells. 1995;13 Suppl 2:118–21.PubMed
54.
Kumar S, Lacy M, Dispenzieri A, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004;34(2):161–7.PubMedCrossRef
55.
Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant. 2002;30(10):673–9.PubMedCrossRef
56.
Gertz MA, Kumar S, Lacy MQ, et al. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood. 2010;115(12):2348–53.PubMedCrossRef
57.
Lee S, Yoon J, Shin S, et al. Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma. Ann Hematol. 2014;93(4):627–34.PubMedCrossRef
58.
Harousseau J, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005–01 phase III trial. J Clin Oncol. 2010;28(30):4621–9.PubMedCrossRef
59.•
Moreau P, Cavo M, Sonneveld P, et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014;32(20):2173–80. This study analyzes date from a large cohort of patients undergoing ASCT after bortezomib induction. It establishes a risk score involving lactate dehydrogenase, International Staging System 3, and the presence of t(4;14) and/or del17p as risk factors for early death after ASCT.PubMedCrossRef
60.
Siegel D, Desikan K, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93(1):51–4.PubMed
61.
Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant. 2006;37(10):917–22.PubMedCrossRef
62.
Kumar S, Dingli D, Lacy M, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol. 2008;83(8):614–7.PubMedCrossRef
63.
Gertz M, Lacy M, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and 17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106(8):2837–40.PubMedCentralPubMedCrossRef
64.
Fonseca R, Bergsagel P, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210–21.PubMedCentralPubMedCrossRef
65.
Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol. 2004;125(1):64–8.PubMedCrossRef
66.
Chang H, Qi X, Samiee S, et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant. 2005;36(9):793–6.PubMedCrossRef
67.
Chang H, Qi X, Jiang A, Xu W, Young T, Reece D. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 2010;45(1):117–21.PubMedCrossRef
68.
Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116(14):2543–53.PubMedCrossRef
69.
Terragna C, Renzulli M, Remondini D, et al. Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation. Ann Hematol. 2013;92(9):1271–80.PubMedCrossRef
70.
Shaughnessy JJ, Zhan F, Burington B, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276–84.PubMedCrossRef
71.
van Rhee F, Szymonifka J, Anaissie E, et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood. 2010;116(8):1220–7.PubMedCentralPubMedCrossRef
72.•
Chng W, Dispenzieri A, Chim C, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–77. This review paper highlights prognostic factors in MM.PubMedCrossRef
73.
Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–30.PubMedCrossRef
74.
Short K, Rajkumar S, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906–8.PubMedCentralPubMedCrossRef
75.
Wu P, Davies F, Boyd K, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50(2):230–5.PubMedCrossRef
76.
Shin H, Kim K, Lee J, et al. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma. Eur J Haematol. 2014
77.
Usmani S, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761–7.PubMedCentralPubMedCrossRef
Metadaten
Titel
Controversies in Multiple Myeloma: to Transplant or Not?
verfasst von
Isabel Ruth Preeshagul
Koen Van Besien
Tomer M. Mark
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 4/2014
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-014-0230-5

Weitere Artikel der Ausgabe 4/2014

Current Hematologic Malignancy Reports 4/2014 Zur Ausgabe

Myelodysplastic Syndromes (M Sekeres, Section Editor)

Lessons from the Atomic Bomb About Secondary MDS

Myeloproliferative Disorders (C Harrison, Section Editor)

Epidemiology of MPN: What Do We Know?

Multiple Myeloma (R Niesvizky, Section Editor)

What We Mean When We Talk About MRD in Myeloma. A Review of Current Methods. Part 1 of a Two-Part Series

Myelodysplastic Syndromes (M Sekeres, Section Editor)

I Walk the Line: How to Tell MDS From Other Bone Marrow Failure Conditions

Myelodsyplastic Syndromes (M Sekeres, Section Editor)

Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks

Myelodysplastic Syndromes (M Sekeres, Section Editor)

I Walk the Other Line: Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndromes

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise